Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232892 · ClinicalTrials.gov registry record · Phase 2
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03232892 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 1 participants.
The verdict
NCT03232892, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Phase II trial to evaluate trametinib in patients with locally advanced non-squamous, non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with progressive disease on at least one prior line of therapy.
Interventions
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03232892
The ClinicalTrials.gov registry entry for NCT03232892 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trametinib is the first listed.
NCT03232892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03232892 about?
NCT03232892 is a clinical study titled "Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer". Phase II trial to evaluate trametinib in patients with locally advanced non-squamous, non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with progressive disease on at least one prior line of therapy.
What is the current status of trial NCT03232892?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-02-13. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03232892?
The interventions under investigation include: Trametinib (DRUG).
Who is sponsoring clinical trial NCT03232892?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.